DMK Pharmaceuticals Corporation

  1. August 05, 2024

    Drug Co. Wants DMK Pharma's $414M Suit Tossed

    Pharmaceutical company US WorldMeds has asked Delaware's bankruptcy court to dismiss a lawsuit accusing it of driving DMK Pharmaceuticals into bankruptcy by inadequately marketing its products, saying the suit lacks sufficient facts to support the claims and seeks exaggerated damages.

  2. July 03, 2024

    Insurer Seeks To Cover D&O Defenses In DMK Pharma Ch. 11

    An insurance company asked a Delaware bankruptcy court Wednesday to let it pay defense expenses under a $5 million directors and officers policy for bankrupt biotechnology company DMK Pharmaceuticals Corp., which is facing an investor lawsuit and two federal agency investigations, arguing the policy proceeds aren't part of DMK's Chapter 11 estate.

  3. May 06, 2024

    DMK Pharma Lands $3.2M Deal To Sell Drug In Ch. 11

    Drugmaker DMK Pharmaceuticals Corp. informed a Delaware bankruptcy judge Monday that the debtor worked out a tentative agreement in its Chapter 11 case to sell an opioid overdose recovery treatment for nearly $3.2 million.

  4. April 09, 2024

    Ch. 11 Judge Tosses Calif. Drug Co.'s Bid To Stay Investor Suit

    A Delaware bankruptcy judge declined Tuesday to apply the automatic stay in DMK Pharmaceuticals' Chapter 11 case to a shareholder's appeal of a Delaware Chancery Court decision before the state's top court, finding the reorganization wouldn't be severely impacted if the debtor tapped an insurance policy to fund its defense.

  5. February 06, 2024

    Drugmaker Eyes Ch. 11 Pivot In Bid To Stave Off Liquidation

    DMK Pharmaceuticals told a Delaware bankruptcy judge Tuesday that it aims to stay financially afloat by narrowing its focus to drugs to combat the opioid crisis, but it won't know for another few weeks if the gamble to avoid a liquidation sale will pay off.

  6. February 05, 2024

    Biotech Co. Hits Ch. 11, Blames Drug Misfires, Criminal Case

    DMK Pharmaceuticals has applied for Chapter 11 protection in Delaware, citing recent clinical trial failures and product recalls, as well as the government's allegation that a subsidiary engaged in criminal activities, as reasons for seeking bankruptcy relief.